BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint
August 31, 2015 at 06:03 AM EDT
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue ...